سعر تايكرب Tykerb‏ 250مجم 70 قرص 2026

Tykerb (lapatinib) 250 mg film-coated tablets, pack of 70 (GlaxoSmithKline / Novartis).

• Most common with capecitabine (>20%): diarrhoea, palmar-plantar erythrodysaesthesia, nausea, rash, vomiting, fatigue. With letrozole (>=20%): diarrhoea, rash, nausea, fatigue.International label, same product · DailyMed (U.S. National Library of Medicine)

• Known severe hypersensitivity (e.g. anaphylaxis) to the product or any of its components.International label, same product · DailyMed (U.S. National Library of Medicine)

• BOXED WARNING - hepatotoxicity: severe and sometimes fatal hepatotoxicity observed; monitor liver function and interrupt/discontinue if severe. Also: decreased LVEF (evaluate before and during treatment), severe diarrhoea, interstitial lung disease/pneumonitis, QT prolongation, severe cutaneous reactions, embryo-fetal toxicity.International label, same product · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inhibitorsAvoid; if unavoidable consider reducing the lapatinib dose.DailyMed (U.S. National Library of Medicine)
• Strong CYP3A4 inducersAvoid; if unavoidable consider gradual dose increase of lapatinib.DailyMed (U.S. National Library of Medicine)
• Substrates of CYP3A4, CYP2C8 or P-glycoproteinLapatinib is likely to increase their exposure.DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm; advise females of reproductive potential to use effective contraception during treatment and for 1 week after the last dose.International label, same product · DailyMed (U.S. National Library of Medicine)
• Advise women not to breastfeed during treatment and for 1 week after the last dose.International label, same product · DailyMed (U.S. National Library of Medicine)